Clinical trials: sponsored by National Cancer Institute (NCI)
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
- Trial name
- NCT07667400
- Testing
- SX-682, DTX
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Leukemia
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Study Description: ELEA is an observational cohort study that will collect exposure information and biospecimens from the adult children of the Agricultural Health Study (AHS) cohort (https://aghealth.nih.gov/about; Protocol…
- Conditions
- Prostate Cancer, Leukemia, Breast Cancer, Melanoma
- Trial name
- NCT07328516
- Where
- United States
- Volunteers
- 64,277 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors
This randomized clinical trial studies peer navigator education in improving survivorship care in African American breast cancer survivors.
- Trial name
- NCT01450020
- Testing
- educational intervention, questionnaire administration, counseling intervention
- Where
- United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Leukemia, Lymphoma
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Background: After an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient s circulation and tissues.
- Conditions
- Leukemia, Lymphoma, Hematologic Malignancy
- Trial name
- NCT06856226
- Testing
- Arm 1
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid…
- Trial name
- NCT06317649
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 229 sites in United States, Canada and 1 more
- Volunteers
- 147 people
- Sponsor
- National Cancer Institute (NCI)
Primary Mediastinal Large B-Cell Lymphoma
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL).
- Trial name
- NCT04759586
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 233 sites in United States, Australia and 2 more
- Volunteers
- 244 people
- Sponsor
- National Cancer Institute (NCI)
Tobacco Products, Smoking Behavior
Communicating About Nicotine Reduction in Cigarettes
The goal of this clinical trial is to learn how a messaging campaign about reduced nicotine cigarettes and policy, combined with the use of very low nicotine cigarettes (VLNCs), affects smoking behavior and attitudes among adult…
- Conditions
- Tobacco Products, Smoking Behavior, Cigarette Use
- Trial name
- NCT06787937
- Testing
- VLNC messages, Control message
- Where
- 2 sites in United States
- Volunteers
- 1,230 people, healthy volunteers welcome
- Sponsor
- Georgia State University
Acute Myeloid Leukemia
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT07437950
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine
- Where
- 59 sites in United States, Puerto Rico
- Volunteers
- 126 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Glioma, Malignant Glioma
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma.
- Trial name
- NCT05717153
- Testing
- Biospecimen Collection, Computed Tomography, Eflornithine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 582 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06694454
- Testing
- azacytidine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Core Binding Factor Acute Myeloid Leukemia
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute…
- Trial name
- NCT06917911
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Cytarabine
- Where
- 81 sites in United States, Puerto Rico
- Volunteers
- 162 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Subject
Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities
This randomized pilot research trial studies how well Eat, Move, Live (EML) works in reducing chronic disease risk in medically vulnerable communities.
- Trial name
- NCT02513407
- Testing
- Behavioral Dietary Intervention, Educational Intervention, Exercise Intervention
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
NSCLC, Non-Small Cell Lung Cancer
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
Background: Immunotherapy is a type of treatment that works by making the body s own immune system stronger. These treatments are used for cancers such as non small cell lung cancer (NSCLC); thymic carcinoma (TC); or metastatic…
- Conditions
- NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT07902921
- Testing
- STAR0602, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
B-All, Acute Lymphoblastic Leukemia
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL.
- Trial name
- NCT05621291
- Testing
- NGS testing
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Localized Malignant Solid Neoplasm, Anal Cancer
Distance-Based Exercise to Preserve Function and Prevent Disability
This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home.
- Conditions
- Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer
- Trial name
- DEFEND (NCT07059884)
- Testing
- Exercise intervention, Telemedicine, Aerobic Exercise Intervention
- Where
- 30 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ampulla of Vater Carcinoma, Appendix Carcinoma
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
This clinical trial is being done to learn whether using the proactive, graduated dose modification algorithm for leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) (PAGODA) algorithm to guide chemotherapy dosing for the…
- Conditions
- Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile, Colon Carcinoma
- Trial name
- NCT07283939
- Testing
- PAGODA algorithm, Oxaliplatin, Folinic Acid
- Where
- 398 sites in United States, Guam and 1 more
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06498635
- Testing
- Biospecimen Collection, Computed Tomography, Durvalumab
- Where
- 284 sites in United States
- Volunteers
- 306 people
- Sponsor
- National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a…
- Trial name
- NCT07388524
- Testing
- Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection
- Where
- 133 sites in United States
- Volunteers
- 336 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Screening
Impact of Protect Your Colon™ on CRC Screening
The purpose of the research is to assess the impact of Protect Your Colon™, a colorectal cancer (CRC) screening decision aid, on patients' CRC screening behaviors.
- Trial name
- NCT05929820
- Testing
- Protect Your Colon™
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Cedars-Sinai Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.